Such knowledge would lay the foundation for testing the therapeutic potential of TRAF3 gene therapy, mitochondria-targeting drugs, and pharmacological inhibitors of metabolic enzymes/transporters in histiocytic sarcoma, osteosarcoma, and epithelial cell-derived cancers of various tissues, especially those with TRAF3 deletions or relevant alterations. This evidence concerns the gene TRAF3 and cancer.